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Background. Cardiotoxicity is a detrimental side eﬀect of the anticancer drug doxorubicin (DOX), characterized by progressive
heart dysfunction. Circulating microRNAs (miRNAs) are recognized as potential biomarkers of cardiac disease; thus, we aimed
to investigate their association with late cardiotoxicity in an animal model of disease. Methods. Twenty C57BL/6 female mice
were administered with 24mg/kg cumulative dose of DOX or saline during 2 weeks, followed by a recovery period of one
month (T42). Echocardiography was performed at baseline and at T42, and plasma samples were collected at T42. The selection
of all miRNAs of interest was conducted by literature overview and by screening, followed by RT-qPCR validation. Results. The
analysis of cardiac function at T42 evidenced ﬁve DOX-treated animals indistinguishable (NoTox) from controls (CTRLs), while
four presented heart impairment (Tox). Our analyses identiﬁed eight dysfunction-associated plasma miRNAs. In particular,
seven miRNAs were found downregulated in comparison to CTRLs, miR-1-3p, miR-122-5p, miR-127-3p, miR-133a-3p,
miR-215-5p, miR-455-3-p, and miR-499a-5p. Conversely, miR-34a-5p showed increased levels in Tox plasma samples.
Noteworthy, we determined a cluster composed of miR-1-3p, miR-34a-5p, miR-133a-3p, and miR-499a-5p that distinguished
with high-accuracy Tox from NoTox mice. Conclusion. This is the ﬁrst study indicating that, similarly to what is observed in
patients, DOX-administered animals present a diﬀerential cardiac response to treatment. Moreover, our results indicate the
presence of speciﬁc plasmamiRNAswhose expression reﬂect the presence of cardiac dysfunction in response to drug-induced injury.
1. Introduction
Doxorubicin (DOX) is a chemotherapeutic agent belonging
to the family of anthracycline drugs. It is currently used
to treat several types of tumors, including breast cancer,
leukemia, and lymphomas [1], but its administration is lim-
ited by cumulative dose-related cardiotoxicity [2]. Indeed,
patients may experience cardiac symptoms varying from
mild ventricular dysfunction to severe heart failure, possibly
leading to heart transplantation [3]. According to recent
guidelines by the American Society of Echocardiography
and the European Association of Cardiovascular Imaging,
cardiotoxicity is deﬁned as a decline of left ventricular
ejection fraction (LVEF) greater than 10 points [4]. It is very
diﬃcult to predict which patient will develop such an impair-
ment, since it can occur either early during treatment or
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several years after administration. Thus, timely diagnosis of
dysfunction onset is of paramount importance for those
patients at risk of developing cardiac damage. LVEF echocar-
diographic monitoring, nuclear imaging, and, when indi-
cated, endomyocardial biopsy are currently used to detect
and monitor cardiotoxicity [5]. Unfortunately, these tech-
niques share a limitation consisting in late diagnosis of heart
impairment occurrence. In the last years, several circulating
markers have been investigated with the aim of early assess-
ment and prediction of cardiac dysfunction onset. Among
them, cardiac troponins (cTn) and brain natriuretic peptide
(BNP) possess the highest sensitivity and reliability [6], but
there is still a need of additional tools for timely and precise
assessment of myocardial injury severity and progression.
MicroRNAs (miRNAs) are small (22–24 nucleotides)
endogenous noncoding RNAs that are involved in post-
transcriptional regulation of gene expression via inhibition
and/or degradation of target messenger RNAs (mRNAs).
Their activity can inﬂuencemultiple biological processes such
as proliferation, diﬀerentiation, development, and cell death
[7], and their dysregulation is accountable for various pathol-
ogies, including cancer and cardiac diseases [8]. In recent
years, miRNAs emerged as possible speciﬁc biomarkers of
several conditions because of their stable expression in almost
all body ﬂuids (e.g., blood, serum, plasma, urine, and saliva)
and due to the development of accurate and quantitative tech-
niques for their detection [9]. In particular, several groups
investigated the potential use of circulating miRNAs in the
diagnostic and/or prognostic setting of cardiovascular dis-
eases, in order to formulate tailored therapeutic strategies
[10]. A limited number of preclinical studies focused on
the association of circulating miRNAs with DOX cardiotoxi-
city, mainly in the acute phase of treatment and for mecha-
nistic insights rather than diagnostic purposes [11]. The
present study aimed at investigating speciﬁc plasma miRNAs
associated to late stages of DOX-induced cardiac damage in
a mouse model.
2. Methods
2.1. Animal Model of Cardiotoxicity. C57BL/6 female mice
(Charles River Laboratories), aged 10 weeks old, were admin-
istered with either saline (CTRL, n = 10) or doxorubicin
hydrochloride (DOX, n = 10, cumulative dose 24mg/kg,
Sigma-Aldrich) by intraperitoneal injections (4mg/kg) 3
times a week for 2 weeks, as previously reported [12]. Female
mice were selected to mimic female breast cancer patients.
The study was carried out in strict accordance with the
recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the Ethics
of Animal Experiments of the University of Milan and by the
Italian Ministry of Health (approval number 379/2015-PR).
The mortality rate was 0% in CTRL animals, while one
DOX-treated mouse died two weeks after the end of
DOX treatment for unknown reasons and was removed
from the study. Thus, the ﬁnal number of DOX-treated
mice was 9.
2.2. Cardiac Function Evaluation. Heart function was
monitored by echocardiography using a Vevo 2100 high-
resolution imaging system (VisualSonics) before treatment
(T0; baseline) and forty-two days (T42) after ﬁrst injection
(Figure S1). Induction of anesthesia was performed using
2% isoﬂurane (Merial) mixed with 100% oxygen (2minutes)
in an induction chamber. The mice were then placed on a
heat pad in a supine position and kept at 37°C to minimize
ﬂuctuations of body temperature. Data acquisition was
performed in mice lightly anesthetized with 0.5% to 1% iso-
ﬂurane, in order to maintain heart rate≥ 450 beats/min.
Two-dimensional short-axis M-mode echocardiography
was performed, and left ventricular end-systolic volume
(LVSV), left ventricular end-diastolic volume (LVDV), and
internal end-systolic and end-diastolic diameters (LVSD,
LVDD) were measured; left ventricular ejection fraction
(LVEF) and left ventricular fractional shortening (LVFS)
were computed.
2.3. Evaluation of Plasma Cardiac Troponin and BNP.
Cardiac troponin I was measured in plasma samples
(n = 4/group) at T42 using the mouse cardiac Tn-I (high
sensitivity) kit (Life Diagnostics), following the manufac-
turer’s instructions. Plasma BNP was measured in plasma
samples (n = 4/group) at T42 using the mouse BNP-EIA
kit (RayBiotech), following the manufacturer’s instructions.
2.4. Sample Collection. At sacriﬁce (T42), animals were anes-
thetized by CO2 overdose followed by cervical dislocation.
Then, blood was collected into EDTA-coated tubes, immedi-
ately centrifuged to separate plasma as previously described
[13], and stored at −80°C until further use.
2.5. Total RNA Puriﬁcation. Total RNA puriﬁcation from
200μL of plasma/sample was conducted using TRIzol (Life
Technologies) following a modiﬁed protocol [14] for liquid
specimens. RNA pellets were resuspended in RNAse-free
water. Since RNA quantiﬁcation from plasma is not possible,
the samples were stored at −80°C until further use.
2.6. MicroRNA Screening. miRNA expression proﬁling was
conducted at T42 using the TaqMan rodent microRNA A
array v2.0 (Applied Biosystems), following the manufac-
turer’s protocol for liquid specimens. The screening was per-
formed on four plasma samples from each group. Data were
analyzed using ExpressionSuite v1.0.3 dedicated software
(Life Technologies), using the global normalization method,
and all miRNAs presenting Ct values> 28 were considered
as not expressed. All miRNAs showing a fold change≥ 2
and a p value < 0.05 were selected for single-assay-based
validation. Moreover, a few additional miRNAs were ana-
lysed, basing on their known involvement in cardiac diseases
[13–15]: miR-1-3p, miR-133a-3p, and miR-499a-5p.
2.7. Single-miRNA Assays. MicroRNA retrotranscription
was conducted using TaqMan Advanced miRNA cDNA
synthesis kit (Life Technologies) starting from 2μL of total
RNA. Expression levels of screening-selected miRNAs were
evaluated using single TaqMan advanced miRNA assays
(Life Technologies), following the manufacturer’s protocol.
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Plasma miR-27-3p was selected as normalizer basing on
screening results as previously described [16]. Indeed, it
showed a strong expression in all samples with very limited
intragroup variability when used for normalization. These
observations were conﬁrmed also by using the NormFinder
(http://moma.dk/normﬁnder-software) software.
2.8. Statistical Analysis. A clustering analysis was performed,
considering the assessed cardiac functional parameters
(LVEF, LVFS, LVSD, LVDD, LVSV, and LVDV), in order
to identify sample groups in an unsupervised fashion. The
GENE-E software (http://www.broadinstitute.org/cancer/
software/GENE-E/index.html) was used to draw heatmaps
and dendograms. The dissimilarity matrix was computed
on the basis of the Pearson’s correlation. AMultidimensional
scaling (MDS) in three dimensions was implemented to eval-
uate the discrimination power of selected diﬀerentially
expressed miRNAs; the goodness of the grouping was evalu-
ated by the average of the silhouette indexes (aSI) [17–19].
Diﬀerences in cardiac functional parameters was assessed
by the Kruskal–Wallis test, (GraphPad Prism 5 software)
while diﬀerences in miRNA expression level were evaluated
by a two-way ANOVA, considering the treatment response
and the time (T0 and T42) as sources of variability. The
Tukey post hoc test was used to evaluate diﬀerences between
each category pair. The “car,” “cluster,” and “stats” [20] R
packages were exploited for this purpose. p values < 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Heterogeneous Cardiotoxic Eﬀects of Doxorubicin on
Mice. In order to identify circulating miRNAs associated to
adverse cardiac response to DOX, we assessed the onset of
cardiotoxicity by cardiac echocardiography at baseline (T0)
and 42 days (T42) after ﬁrst injection (Figure 1). In particu-
lar, unsupervised clustering analysis of cardiac functional
parameters indicated that some DOX-treated animals pre-
sented a heterogeneous response to drug administration at
T42 (Figure 2). Indeed, basing on heart function data, ﬁve
treated mice (NoTox) grouped with the CTRL animals, while
a cluster of four mice (Tox) diverged from both CTRLs and
NoTox. Of note, the same analysis, performed using base-
line data, showed that all animals grouped together before
DOX treatment, as conﬁrmed by quantitative analysis of
the six cardiac parameters. Diﬀerently, when considering
the data obtained at T42, Tox mice showed impaired heart
function vs. both NoTox and CTRL animals (Figure 3 and
Supplementary Table 1). In particular, they presented a sig-
niﬁcant reduction in LVEF and LVFS, a strong increase in
LVSV and LVDV, and a moderate rise in LVDD and LVDV.
The comparison between T0 and T42 evidenced a detrimen-
tal eﬀect of DOX only in the Tox group. Diﬀerently, CTRL
and NoTox animals showed no appreciable variations in
heart function throughout the duration of the experiment.
Cardiac troponin I and BNP levels were measured as indica-
tors of cardiac damage and dysfunction at T42. Interestingly,
no variations from CTRL levels were observed for both
markers in either NoTox or Tox animals (Figure S2).
3.2. Plasmatic miRNA Proﬁling and Validation at T42.
With the aim of identifying plasma miRNAs potentially
associated to long-term post-DOX treatment, we conducted
an array-based screening comparing CTRL, NoTox, and
Tox samples at T42. We found fourteen miRNAs potentially
regulated (p < 0 05) among all the groups (not shown). In
particular, after validation, eight miRNAs evidenced a sig-
niﬁcant dysregulation in their plasma expression (Figure 4
and Supplementary Table 2). Interestingly, two miRNAs,
miR-1-3p and miR-499a-5p, showed a strong decrease in
Total cumulative dose
24 mg/kg
Single intraperitoneal injection
Echocardiography
Treatment Recovery
1 week 2 weeks 3 weeks 6 weeks5 weeks4 weeks
To T42
Figure 1: Experimental design. Treatment protocol for our animal model of DOX-induced cardiotoxicity. Arrows indicate single 4mg/kg
intraperitoneal DOX/saline injections. The horizontal blue bars indicate experimental endpoints when echocardiography was conducted.
Each group was composed of ten animals.
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the Tox group in comparison to both CTRLs and NoTox
groups. Diﬀerently, miR-122-5p was decreased only in
the NoTox group (when compared to CTRLs and Tox
mice), similarly to miR-455-3-p (vs. CTRLs only). In addi-
tion, miR-127-3p, miR-133a-3p, and miR-215-5p showed a
signiﬁcant downregulation in Tox vs. the CTRL groups,
while miR-34a-5p was upregulated.
3.3. Circulating miRNA-Based Distinction of DOX-Aﬀected
from DOX-Unaﬀected Mice. These results prompted us to
investigate whether DOX-regulated miRNAs could be used
to distinguish drug-aﬀected from drug-unaﬀected animals.
Thus, we performed a Multidimensional scaling analysis
basing on the expression of all eight regulated miRNAs. As
shown in Figure 5(a), this miRNA signature correctly
discriminated CTRLs from NoTox and Tox animals, as indi-
cated by the calculated average silhouette indexes (0.10).
Then, we conducted the same analysis only on DOX animals,
in order to identify those miRNAs with the best discrimina-
tory potential between Tox vs. NoTox mice. We identiﬁed a
cluster composed of four miRNAs (miR-1-3p, miR-34a-5p,
miR-133a-3p, and miR-499a-5p) with the better discrimi-
natory potential between the two groups (aSI: 0.44).
Indeed, a complete partition could be observed between
DOX-aﬀected and DOX-unaﬀected mice (Figure 5(b)).
4. Discussion
This is the ﬁrst study showing that, similarly to cancer
patients, animal models do not homogeneously respond to
anthracycline treatment. The main ﬁnding of this work is
that circulating miRNAs discriminate drug-aﬀected from
drug-unaﬀected animals after a long-term doxorubicin expo-
sure. In clinical practice, the most important DOX-related
issue relies in the timely detection of cardiac complications
in treated patients, usually occurring even years after admin-
istration [21]. The correct identiﬁcation of subjects at high
risk of cardiac dysfunction onset is, in fact, of utmost
importance to ensure appropriate interventions [11]. In
our murine model, cardiotoxicity was induced by serial
injections of doxorubicin. Interestingly, the presence of heart
dysfunction, although suggested by the alteration of some car-
diac parameters, was not clearly evident in long-term recover-
ing animals. Thus, diﬀerently from previous works [22], we
decided to perform a thorough evaluation of cardiac parame-
ters in order to assess the real eﬀects of the drug on treated
animals. Surprisingly, our analysis evidenced a signiﬁcant dif-
ference of cardiac response to DOX administration among
treated mice. Indeed, we identiﬁed a cluster of animals dis-
playing either none or negligible functional defects (NoTox),
while another group showed a strong cardiac impairment due
to the drug (Tox). Consistent with this observation, our array-
based screening led to the identiﬁcation of several regulated
plasma miRNAs both in Tox and NoTox animals in compar-
ison to controls. Interestingly, we assessed a DOX-induced
upregulation of miR-34a-5p only in plasma of Tox animals.
This result is in line with a previous work indicating a
miR-34a-5p increase at circulating levels [11] upon acute
anthracycline administration, although we are the ﬁrst to
report its regulation after a long-term release from treat-
ment. Intriguingly, beside DOX-induced cardiotoxicity
[23], increased circulating levels of miR-34a-5p have been
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Figure 2: Diﬀerential cardiac response to doxorubicin treatment. Unsupervised clustering based on cardiac functional parameters at T0 (a)
and T42 (b). At T0, all animals were grouped together. At T42, a cluster of drug-treated animals was clearly separated (Tox) from those
unaﬀected (NoTox) by doxorubicin and CTRLs. Cardiac functional parameters: LVEF: left ventricular ejection fraction; LVFS: left
ventricular fractional shortening; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; LVDV: left
ventricular diastolic volume; LVSV: left ventricular systolic volume.
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associated with ventricular remodelling [24] and heart failure
onset [25, 26] following myocardial infarction. Moreover, its
inhibition seems to have beneﬁcial eﬀects against cardiac
dysfunction [27], hinting at its possible clinical exploitation
both as a biomarker and therapeutic target.
An interesting ﬁnding was represented by the observed
dysregulation, in the Tox group, of miR-1-3p, miR-133a-
3p, and miR-499a-5p, previously observed to be increased
in plasma of patients suﬀering from cardiac damage [28].
In particular, the circulating expression of the latter has
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previously been associated to plasma troponin levels dur-
ing infarction [29]. Surprisingly, though, these three miR-
NAs showed a strong decrease in Tox animals at T42
when compared to CTRL and NoTox animals, possibly
because of a response mechanism triggered by treatment.
Noteworthy, during our experiments, we did not observe
any perturbation in plasma levels of cardiac troponin I
and BNP, both considered as the most important markers
of cardiotoxicity [30, 31]. These results, though, seem not
to be an uncommon event for in vivo studies [32], and we
cannot exclude that technical limitations somehow inﬂuenced
the results.
Among the other regulated miRNAs, only miR-215-5p
was previously shown to be “positively” perturbed upon
chronic doxorubicin treatment, although it was found upreg-
ulated in rat hearts at diﬀerent times and amount of admin-
istered drug [33]. In regard to miR-127-3p, its role in heart
physiology and cardiotoxicity has never been assessed,
although it was found downregulated in patients suﬀering
from acute pancreatitis associated with lung injury [14, 34].
Interestingly, both miR-122-5p and miR-455-3p showed a
diﬀerential expression only in the NoTox group, again
possibly because of some unknown eﬀects triggered by heart
dysfunction in Tox animals. Of note, plasma miR-122-5p,
despite being known as liver-speciﬁc, has been already
reported to be negatively regulated in cardiovascular diseases
[35]. As for miR-455-3p, it was demonstrated to be an
enhancer for hypertrophy in a murine model, but, at the
same time, it reduced the progressive deterioration of left
ventricular function [36, 37].
The principal novelty of this work relies on the identiﬁca-
tion of a miRNA signature that separates with good eﬃciency
drug-aﬀected both from drug-unaﬀected and control mice.
Indeed, the whole set of DOX-regulated miRNAs showed a
good accuracy in separating the three “functional” groups
of animals. Our analyses, though, showed that not all DOX-
regulated miRNAs were necessary to correctly separate the
groups of animals. Notably, a subsignature composed of four
out of eight circulating miRNAs regulated by DOX showed to
be suﬃcient to correctly identify Tox from NoTox animals.
Some limitations of this work should be acknowledged.
Since we used healthy animals, tumor contribution to the
plasmatic composition of miRNAs and possible detrimental
systemic eﬀects of cancer could not be assessed. Indeed, the
expression of some circulating miRNAs, including miR-
34a-5p, is known to be aﬀected by some tumors [38], but
we decided to focus our attention on cardiac eﬀects of the
drug in a “clean environment.” Nevertheless, our results par-
tially overlap (at least for miR-1-3p) with those from recent
investigations conducted on cancer patients [14], although
we are aware that the time frame evaluated in our animal
model is not comparable to those evaluated in clinical
studies. We are aware that by focusing only on female mice,
we partly reduced the strength of our ﬁndings. Nevertheless,
since our aim was mimicking female breast cancer patients,
we feel that including male subjects in our study could
result in the unwanted addition of possible confounding
variables. Since oestrous cycle was not evaluated, a possi-
ble inﬂuence on the cardiotoxic process described here
cannot be excluded. Female reproductive hormones have
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Figure 4: Plasma miRNAs are regulated upon doxorubicin treatment. Eight miRNAs showed dysregulated expression upon DOX treatment
(vs. CTRL). Data are depicted as scatter plots and expressed as mean fold change± SD vs. CTRL, arbitrarily set to 1. Controls: blue dots,
NoTox: green dots, Tox: red dots. ∗p < 0 05. CTRL n = 10; NoTox n = 5; Tox n = 4.
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been proposed to be associated with cardioprotective
states; however, although several mechanisms have been
suggested for the possible underlying mechanism, no study
elucidated the potential changes of the cardiac tissue dur-
ing speciﬁc stages of the oestrous cycle. Evaluating the
inﬂuence of ﬂuctuating oestrous cycle hormones on car-
diac tissue remodelling was out of our aim, and we believe
that this topic deserve a speciﬁc investigation. In addition,
beside baseline and long-term data, we did not evaluate
miRNAs and functional cardiac parameters in the acute
phase of treatment. Indeed, we decided to focus on the
follow-up period, usually the most critical time for cardio-
toxicity onset, and the one never previously investigated in
animal models. Further, patient-based investigations are
needed to verify whether our ﬁndings can be applied to
the clinical setting. Anyhow, we demonstrated, for the ﬁrst
time, the existence of a heterogeneous cardiac functional
response to DOX over time, which is reﬂected by variation
of expression of speciﬁc clusters of circulating miRNAs.
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Supplementary Materials
Supplementary 1. Supplementary Figure S1: echocardio-
graphic imaging. The panel depicts three representative
two-dimensional short-axis echocardiographic images
(M-mode) of CTRL, NoTox and Tox groups at T0 (left) and
T42 (right). No diﬀerences were observed among the groups
at T0, while the Tox group showed signs of dysfunction
at T42.
Supplementary 2. Supplementary Figure S2: plasma troponin
I andBNP levels. PlasmaTnI andBNP levelsweremeasured in
CTRL (blue bars) and NoTox (green bars) and Tox (red bars)
animals (n = 4/group) at T42. No diﬀerences were observed
among any group. Values are expressed as mean± SD.
Supplementary 3. Supplementary Table S1: cardiac function
parameters of treated and control animals and p values of
performed comparisons. Parameter values are expressed as
mean± SD.
Supplementary 4. Supplementary Table S2: fold change data
of regulated miRNAs. Values are expressed as mean± SD.
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cardiac responses to doxorubicin. (a) All Tox miRNAs were used for unsupervised clustering. A good accuracy was observed in separating
the three groups of animals. (b) We identiﬁed a restricted miRNA cluster (miR-1-3p, miR-34a-5p, miR-133a-3p, and miR-499a-5p)
correctly separating Tox/NoTox mice. Blue: CTRL; green: NoTox; red: Tox. aSI: average silhouette index. CTRL n = 10; NoTox n = 5;
Tox n = 4.
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